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Pulmonary infections in the returned traveller are a common presentation. A wide variety of infections may present
with pulmonary symptoms. It is important for clinicians to differentiate the cause of these symptoms. The risk
of contracting certain travel-related pulmonary diseases depends on travel destination, length of stay, activities
undertaken and co-morbidities. Some pathogens are found worldwide, whilst others are related to specific
locations. This review article will discuss the approach to diagnosing and treating pulmonary infections in the
returned traveller.
Keywords: Travel, Traveller, Pulmonary infections, Tropics, Respiratory infectionsBackground
International travel has steadily increased over the last few
decades, and is no longer only for the wealthy and healthy.
The number of travellers reached more than one billion
for the first time in 2012 and continues to rise [1]. There
are many risk factors that increase the likelihood of de-
veloping a travel-related illness and this review will
focus on pulmonary-related infections (Table 1) [2–4].
Many illnesses are self-limiting and are a result of com-
mon pulmonary viruses that are prevalent worldwide
[3, 5] but in certain circumstances travel-related pul-
monary infections are serious and have potentially fatal
implications, and can even cause epidemics.
Air travel has shown how efficiently pulmonary infec-
tions can be transmitted. Data suggests the risk of dis-
ease transmission to a symptom-free passenger within
the aircraft cabin is associated with sitting within 2
rows of a contagious passenger for a flight time of more
than 8 h. This association is mainly derived from inves-
tigations of in-flight transmission of tuberculosis (TB)
[6]. Aircraft cabin ventilation appears to be a key factor
enabling disease transmission. This was highlighted by
the spread of severe acute respiratory syndrome (SARS)
during a short-haul flight in 2002 [5]. With sea travel
(especially cruising) becoming more popular, the ageing* Correspondence: a.trimble@nhs.net
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ditions is also a concern.
Clinicians should be aware of particular diseases that
may present in the returned traveller and rank their
diagnostic likelihood based on destination, length of stay
and symptom duration (Tables 2 and 3).
Pneumonia is a frequent cause of fever amongst
returned travellers [7]. Awareness of travel locations may
be key to identifying the organism responsible, and poly-
merase chain reaction (PCR) testing is very important to
look for atypical etiologies. Routinely, patients are started
on antibiotics based on local guidelines for community-
acquired pneumonia. It is unlikely these regimens will
contain appropriate first-line therapy or be of sufficient
duration to cover for pneumonias caused by Coxiella
burnettii (Q fever) [8] or Burkholderia pseudomallei
(melioidosis), which have been isolated in recent outbreaks
that have occurred in Europe and South East Asia [9].
Pulmonary infections are diagnosed in up to 24% of
returned travellers with fever, making it as common as
travellers’ diarrhea, with influenza being the most com-
mon vaccine-preventable infection acquired (vaccine
protective against H1N1, H3N2 and two influenza B
virus strains) [10, 11]. Pre-travel advice should be that
travellers with co-morbidities should be vaccinated
against both seasonal influenza virus and pneumococ-
cus [12]. It should be noted that the influenza vaccine
does not currently offer protection against the most
recent strains causing epidemics (H5N1, H7N9) andle is distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Specific Risk factors
Risk activities Common Occasional
Bites
Tick Q fever
Mosquitos Tropical eosinophilia
(Wuchereia bancrofti
and Brugia malayi)
Dirofilarisis
Animal Avian influenza,
Nipah virus, Hantaan
virus, MERS
Q fever, tularemia,
plague, SARS
Dust exposure
(e.g., caves or
deserts)
Coccidioimycosis,
histoplasmosis
Cruise ships/resorts Legionella
Rural/Farm Q fever
Soil Strongyloidiasis,
hookworm, ascariasis
Melioidosis
Fresh-water
exposure
Schistosomiasis,
leptospirosis
Ingestion
Undercooked/
raw food
Paragonimus,
toxocariasis,
hydatidosis
Sexual exposure HIV
Host factors
Immunocompromised Tuberculosis
SARS severe acute respiratory syndrome, MERS Middle Eastern respiratory
syndrome, HIV human immunodeficiency virus
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travel and length of stay in affected areas [13].
In this review, we will discuss various pulmonary infec-
tions that are more common in returned travellers. A clear
and thorough approach to a symptomatic returned travel-
ler is an essential skill for the acute/general physician and
general practitioner (Table 4). Particular attention should
be given to infections that may spread by human-to-Table 2 Incubation periods of pulmonary infections
Incubation Period Infection
Short (<10 days) Viral: influenza, SARS, MERS, Nipah
Bacterial: common organisms causing
pneumonia (Streptococcus pneumoniae,
Haemophilus influenzae), melioidosis,
Legionellosis, plague, pertussis, diphtheria
Fungal: histoplasmosis
Medium (10–21 days) Viral: MERS, Nipah, hantavirus
Bacterial: pertussis, melioidosis
Fungal: histoplasmosis, coccidioidomycosis
Eosinophilic: ascariasis, hookworm, strongyloides,
toxocariasis
Long (>21 days) Bacterial: Q fever, TB
Eosinophilic: schistosomiasis, hydatidosis,
dirofilariasis, paragonomiasis, Wuchereia bancrofti,
Brugia malayi
SARS severe acute respiratory syndrome, MERS Middle Eastern respiratory
syndrome, TB tuberculosishuman transmission. Clinicians should be aware of where
to source information should they suspect a travel-related
infection or if they have concerns for public health. Infec-
tions related to travel are constantly evolving and it is
important for clinicians to remain up to date with current
disease outbreaks and management recommendations.
Pulmonary infections caused by viruses and
bacteria
Upper pulmonary infections are more common than
lower pulmonary infections. In general, the types of pul-
monary infections that affect travellers are similar to those
in non-travellers, and exotic causes are rare [2, 13, 14]. An
Australian study collected data over a 3-year period; it
showed around 28% of Australian travellers returning
from Asia developed an acute pulmonary infection within
72 h (defined as an illness episode involving the presence
of at least two upper pulmonary symptoms; e.g., sore-
throat, coryza). This translates to an incidence of 106.4
per 10,000 traveller days. PCR testing on these travellers
was analyzed for influenza A and B virus, adenoviruses,
respiratory syncytial virus (RSV), picornaviruses and para-
influenza viruses 1, 2, and 3. Only 1% of these travellers
acquired influenza A virus, with no data for the other de-
tectable viruses included [15].
There is evidence that contracting a common upper
pulmonary virus potentiates the risk of contracting a
tropical disease as well. A study in 2008 [16] showed
that during an epidemic of chikungunya in India, 87% of
confirmed cases were also co-infected with RSV and
another upper respiratory virus, 41% were co-infected
with RSV alone and 9% were co-infected with influenza
virus and adenovirus. It is likely that a parallel outbreak
of pulmonary viral infections during this time resulted in
higher morbidity and mortality during this epidemic.
Bacterial pathogens are generally not related directly
to a particular travel destination. Streptococcus pneumo-
niae, Mycoplasma pneumoniae, Haemophilus influenzae,
and Chlamydophila pneumoniae are the most common
organisms known to cause pneumonia throughout the
world and risk of infection is not directly related to
travel. More specific illnesses caused by C. burnettii (Q
fever), Legionella pneumophila (Legionella), Bordetella
Pertussis (pertussis), Corynebacterium diphtheriae
(diphtheria) and Leptospira (leptospirosis) are normally
a result of an epidemic within a country [2, 10, 14].
This list may be very relevant to the treating clinician.
Travel to international mass gatherings is a proven risk
factor for the spread of pulmonary infection. For ex-
ample, during pilgrimage to Mecca, pneumonia caused
by S. pneumoniae is the leading cause of hospitalization
and intensive care unit admissions during the Hajj
(nearly 40% of patients). Out of 300 participants less
than 5% had been vaccinated despite 65% being eligible.
Table 3 Causes of pulmonary infections associated with specific geographical areas
Geographical Area Common Occasional Rare but important
Sub-Saharan Africa HIV-associated
pulmonary infections, TB
Katayama syndrome, tropical pulmonary eosinophilia
(Wuchereia bancrofti), Loeffler’s syndrome (hookworm,
strongyloides) hydatidosis
Histoplasmosis, pneumonic plague,
paragonomiasis
North Africa, Middle East
and Mediterranean
Q fever, tropical pulmonary eosinophilia (Wuchereia
bancrofti) Loeffler’s syndrome (hookworm, ascariasis,
strongyloides) hydatidosis, toxocariasis
MERS
Eastern Europe and
Scandinavia
Legionellosis Pertussis, toxocariasis Hantavirus, tularemia
South and Central Asia diphtheria, TB, avian flu Melioidosis, Loeffler’s syndrome (hookworm, ascariasis,
strongyloides) hydatidosis
Nipah virus
Southeast Asia avian flu Melioidosis, tropical pulmonary eosinophilia (Brugia
malayi), Loeffler’s syndrome (strongyloides, hookworm),
leptospirosis, diphtheria
SARS, hantavirus, Nipah virus,
dirofilariasis, Katayama syndrome,
paragonomiasis
Northern Australia Q fever Melioidosis, dirofilarisis, pertussis
Latin America and
Caribbean
Coccidioidomycosis
histoplasmosis, leptospirosis, diphtheria, tropical pulmonary
eosinophilia (Wuchereia bancrofti), Loeffler’s syndrome
(ascariasis, strongyloides), hydatidosis, toxocariasis
Hantavirus, dirofilariasis
North America Legionellosis, pertussis,
diphtheria
Coccidioidomycosis
histoplasmosis, toxocariasis
Dirofilariasis, Q fever
HIV human immunodeficiency virus, SARS severe acute respiratory syndrome, MERS Middle Eastern respiratory syndrome, TB tuberculosis
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diseases for many travellers [12].
Influenza
Particular attention should be paid to travellers returning
from influenza-endemic areas, taking into account newly
reported sub-types. The burden of influenza occurs in the
winter months in temperate regions, in the Northern
Hemisphere from November to April and the Southern
Hemisphere from April to October. In the tropics, the
virus circulates at a low level all year round [17]. Influenza
is diagnosed from viral throat swabs using real time PCR
(rt-PCR) that can differentiate particular influenza sub-
types [18].
Avian influenza sub-type H5N1 virus has caused death
in humans since 1997, predominately in Asia and North
East Africa, with a current upsurge of cases in Egypt.
From 2003 to October 2015, there have been a total of
844 laboratory-confirmed cases with mortality rates ofTable 4 Checklist for taking a travel history
Questions Examples
Country of travel and
accommodation
Latent diseases, possible exposures
Occupation, hobbies,
activities
Healthcare worker, business, visiting relatives,
farmer, cave explorer, water exposure
Prophylaxis Immunizations, prophylaxis, insect repellents
Treatment or procedures Hospital treatment in country, tattoos
Diet Seafood, raw food
Sex Unprotected sex, paid sex, multiple partners
Animals Birds, domestic animals, wildlifemore than 50% [19]. H7N9 is the most recently re-
ported sub-type. It was first diagnosed in March 2013
in China and is characterized by rapidly progressive
pneumonia, pulmonary failure and acute pulmonary
distress syndrome (ARDS) [18]. As of October 2015,
there have been 679 laboratory-confirmed cases, with
275 reported deaths [19].
Treatment of influenza remains a controversial topic
but generally supportive management is adopted. Current
recommendations are early administration of a neuramin-
idase inhibitor (e.g., oseltamivir) to the affected individual
and their close contacts [18]. A recent meta-analysis of
the H1N1 pandemic showed that hospitalized patients
treated with a neuraminidase inhibitor had a lower
mortality, and that this was further reduced by early insti-
gation [20].
Prevention of avian influenza has proved difficult due
to the antigenic diversity of the circulating viruses,
which has hampered vaccine development [21]. Health-
care professionals should take post-exposure prophylaxis
(e.g., oseltamivir) after a patient has been diagnosed with
avian influenza and personal protective equipment is
highly recommended.
Severe acute respiratory syndrome (SARS) and Middle
Eastern respiratory syndrome (MERS)
Like influenza, other viral epidemics are gathering publi-
city, heightening awareness and recognition worldwide.
MERS and SARS are zoonotic coronavirus infections with
regular media coverage due to their symptom severity, as-
sociated mortality rates and anxiety regarding potential
human-to-human transmission. Bats are thought to be the
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compelling evidence that camels are also responsible for
transmission of the MERS coronavirus [22, 23].
SARS was first reported as an atypical pneumonia to
the World Health Organization (WHO) in November
2002 in China and subsequently spread worldwide. The
first reported epidemic occurred in a Hong Kong hotel
in February 2003. The virus was transmitted to 16 hotel
guests who were staying on the same floor as an infected
individual, and the virus spread through international air
travel thereafter. WHO identified the coronavirus re-
sponsible through nasopharyngeal culture within 2 weeks
of this event. More than 30 countries reported affected
individuals, with more than 8,000 confirmed cases
worldwide and a 9.6% mortality rate [24].
The pulmonary symptoms associated with SARS (typ-
ically, non-productive cough and subsequent dyspnea)
did not present until several days after initial exposure
to the virus. As SARS is caused by an airborne virus, the
risk of transmission was greatest amongst those involved
in the direct care of an infected individual. Since no
medications effectively treated SARS, interrupting trans-
mission was the key to controlling the outbreak. Simple
public health measures, such as wearing surgical masks,
offered the most effective protection against transmis-
sion and there were no further confirmed cases as of
July 2003 [24].
The public health lessons learned during the SARS
epidemic have proved invaluable in limiting the spread
of MERS cases worldwide. MERS was first recognized in
September 2012 and, as of October 2015, 1,611 cases
have been reported with more than 570 related deaths
[25]. To date, the largest cluster of cases to occur outside
of the Middle East was reported in South Korea in May
2015. The index case was a businessman who developed
pulmonary symptoms upon returning from a trip to the
Middle East. A total of 185 cases were identified, with
36 deaths (19.5% mortality rate) [26]. This proved the
migrating capabilities of the virus and potential for out-
breaks worldwide. Any clinician who sees an individual
returning from the Middle East presenting with fever
and pulmonary symptoms within 14 days of travel
should consider MERS as a diagnosis and prompt in-
vestigations (diagnosed by nasopharyngeal culture) and
public health control methods should be initiated. No
specific treatments or vaccine have been developed to
date.
As with most infections, the groups with the poorest
outcomes related to MERS infection are the young
(<12 years), the elderly (>65 years), immunocompromised
patients and those with multiple co-morbidities [22].
Clinically, presentation is similar to SARS but MERS has a
longer incubation period and greater severity of pulmon-
ary symptoms and an even higher mortality risk. All casesof MERS confirmed worldwide to date have had a direct
or indirect link with the Middle East—predominately
Saudi Arabia. It has proven to be less contagious than
SARS so far, although it is expected that a more virulent
virus will evolve.
The plague
Where SARS and MERS have attracted much media
coverage, it should not be forgotten that the plague
bacillus (Yersinia pestis) still affects a great number of
people each year [27]. The pneumonic plague has seen en-
demic outbreaks in certain parts of Africa, with sporadic
cases occurring worldwide.
Historically, there have been 3 pandemics involving the
bubonic (swollen, painful lymph nodes) and pneumonic
plague in the 6th century, the 14th century and the 19th
century; however, it also re-emerged in the 1990s with a
more limited distribution [27].
The pneumonic plague occurs as a complication of the
bubonic plague and is the only form capable of trans-
mission from human-to-human via pulmonary droplets.
Clinical sequelae are a dry cough within 24 h of first
exposure, which becomes productive before hemoptysis
occurs with the sputum becoming increasingly more
bloodied within the next 24–48 h—this is a sign of
certain mortality. The major clinical clues in diagnosing
the pneumonic plague are travel history, rapid onset of
symptoms (sometimes hours from being asymptomatic to
fever and cough/hemoptysis) and bilateral pneumonia
[27, 28]. The patient is most contagious when hemoptysis
develops; simple protective measures, such as wearing
masks, help prevent transmission [28].
The last reported outbreak of the pneumonic plague
was in Madagascar in September 2014. There were 263
reported cases, with a 26.9% mortality rate. The plague
has been endemic on the island for the past 30 years—it
is the most severely affected country in the world [29].
While developing countries are at most risk of out-
breaks of the disease, sporadic cases can occur elsewhere.
Four patients were diagnosed in July 2014 with pneu-
monic plague in Colorado, United States of America
(USA). The index patient contracted the disease from his
pet dog. No deaths occurred and all patients rapidly
responded to antibiotic treatment; streptomycin, tetra-
cyclines and sulphonamides are used as the standard
antibiotics, with gentamicin and fluoroquinolones as
alternatives [30]. All close contacts should be given
prophylactic antibiotics and monitored for symptoms.
The plague bacillus has previously been used in bio-
logical warfare during the 20th century. Yersinia Pestis is
an attractive agent due to easy accessibility, simple culture
needs and transmission via aerosol [31]. It is important
point to note that a plague outbreak can be easily con-
trolled with simple public health measures and readily
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the pneumonic plague is almost certainly fatal.
Hantaan and Nipah viruses
Two viral infections noted to be causing outbreaks
throughout the world are the Hantaan (causing hanta-
virus cardiopulmonary syndrome [HPS]) and Nipah
viruses. Both diseases were microscopically discovered in
the 1990s and are zoonotic; they are transmitted to
humans via rodents and via bats and pigs, respectively.
Both have a range of clinical symptoms and may present
with flu-like symptoms continuing onto encephalitis
with Nipah virus or pulmonary failure and cardiogenic
shock in Hantavirus-related infections [32, 33].
The first Nipah outbreak was in Malaysia in 1999; a
total of 276 cases were diagnosed with a 38.4% mortality
rate [34]. The outbreak spread into Singapore and it was
discovered that the virus was transmitted to humans
from pigs; this resulted in a cull of more than 1 million
pigs to control the outbreak. Since then, outbreaks have
occurred in Bangladesh and India with a mortality rate
of around 75% [35]. Most cases presented with pulmon-
ary symptoms (cough, dyspnea and bilateral opacities
covering the majority of the lung fields on chest radio-
graph) and there was a higher human-to-human trans-
mission rate in comparison to the Malaysian outbreak
[36]. The Nipah virus was readily identified in the saliva
of infected patients, allowing easy disease transmission.
There have only been outbreaks of the Nipah virus in
South East Asia to date, but there is potential for this dis-
ease to occur in other countries. The intermediate host
(fruit bats from the Pteropodidae family) has an extensive
habitat distribution and is native to parts of Africa and
northern Australia [37]. The treatment is limited to sup-
portive care—control methods to prevent human-to-
human transmission are very important to stop rapid
spread. Studies have shown the antiviral drug ribavirin
may reduce mortality from the infection [33].
At present, more than 21 Hantaviruses from the
Bunyaviridae family have been identified as causing
illness in humans. Signs of infection range from protein-
uria to pulmonary edema and frank hemorrhagic illnesses
[32]. HPS is most likely to occur in the Americas although
there are sporadic case reports from Europe [38]. The dis-
ease is most likely to be transmitted in areas where sanita-
tion is poor or in rural farming areas. Rodents shed the
virus in their urine, droppings and saliva, and the virus is
transmitted between humans via pulmonary droplets [32].
The first reported outbreak occurred in 1993 in the
USA, although retrospectively it seems the Hantaviruses
have been causing fatal pulmonary illnesses since the
1950s [39]. The cluster of around 30 cases in 1993 oc-
curred in an area of southwest USA known as the ‘Four
Corners’. Clinicians identified a series of cases of a severeand acute pulmonary illness affecting young healthy adults
where non-cardiogenic pulmonary edema developed rap-
idly. To date, more than 600 cases of HPS have been re-
ported in the USA [40]. In 2012, the virus was discovered
at Yosemite National Park where potentially hundreds of
travellers were exposed to the infection. Ten cases of HPS
were confirmed, 3 of which were fatal [41].
Treatment for Hantavirus remains supportive. Intra-
venous fluids should be used with caution, as aggressive
fluid resuscitation is likely to accelerate the progression
to pulmonary edema and failure due to capillary leakage
[32]. Extracorporeal membrane oxygenation (ECMO)
treatment has dramatically reduced mortality rates [42].
The benefits of ribavirin therapy remain undetermined
due to small trial numbers [43]. To date, only one
Hantavirus has evolved to transmit via human-to-
human contact (the Andes virus, named after its geo-
graphical discovery location in 1996).
Accurate diagnosis requires a high degree of suspicion
and should be considered in an individual presenting
from a recent stay in North or South America with rap-
idly progressing pulmonary symptoms and/or signs [32].
The risk to a traveller in contracting any of the above
outbreak diseases remains small given their limited geo-
graphical distribution at present. The risk of exposure
may be increased by several factors (Table 1) such as
activities undertaken, close contact with an infected indi-
vidual, and not seeking appropriate pre-travel informa-
tion or recommendations. As a clinician it is important
to have up-to-date knowledge on current outbreaks occur-
ring worldwide and their relevant geography as prompt
recognition and diagnosis may prevent an epidemic.
Q fever
Q fever, caused by C. burnettii, is a worldwide zoonotic
disease. Outbreaks in humans have been linked to abat-
toirs and carriage of C. burnettii by wind from farms of
affected animals. Ticks can also act as a reservoir. It is
not strictly a travel-related illness but it is most likely
found in areas where contamination with animal waste
is common. It presents as an acute febrile illness with
non-specific signs such as atypical pneumonia [8]. Rural
travelling is the greatest risk factor for acquiring the
disease. Most recently, Q fever outbreaks have occurred
in Hungary, where 70 cases were confirmed by micro-
immunofluorescence testing and treated with 3 weeks of
a tetracycline. No deaths occurred. Efforts to reduce the
spread of Q fever after an outbreak include elimination
of manure and disinfection of affected farms [8].
Legionella
Legionella (L. pneumophila) is a bacterium that can
cause anything from a mild febrile illness to the poten-
tially fatal form of pneumonia known as Legionnaires’
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and the same agent causes sporadic cases and outbreaks.
Outbreaks are typically linked to contaminated water
systems where conditions are ideal for rapid growth of
the organism [44]. In 2014, the WHO confirmed 302
cases of Legionellosis in Lisbon, Portugal, that were
related to a contaminated industrial cooling tower, with
5 deaths as a result of the disease [45]. Most cases are
reported after travel to developed countries in Europe or
North America. At risk individuals are those with co-
morbidities, the elderly, smokers and the immunosup-
pressed. It is caused by inhalation of aerosols containing
the bacterium and accounts for 2–15% of hospital admis-
sions for community-acquired pneumonia, with a summer
or autumn peak [45]. Identification of affected individuals
is by urinary PCR and treatment is with a macrolide
antibiotic [46].
Pertussis and diphtheria
Pertussis and diphtheria are vaccine-preventable pulmon-
ary infections; poor vaccine uptake has led to a recent in-
crease in cases in developed countries. It is important,
therefore, to take a full vaccination history in returned
travellers who present with pulmonary symptoms [47].
Pertussis is a worldwide endemic-epidemic disease
with outbreaks most likely during summer/autumn time.
Pertussis is thought to still cause around 63,000 deaths
per year in children under 5 years of age, although there
is uncertainty over these estimates in view of the paucity
of reliable surveillance data [48].
Recently, there has been an increase in the number of
adolescent and young adults being diagnosed in some
high-income countries, likely due to decreased vaccin-
ation uptake rates and a change in the vaccine itself. It
is thought that the acellular vaccine currently used
appears to have a short-lived immunity leading to
increased infection rates [49]. Macrolide antibiotics are
given to affected individuals to prevent further spread
of pertussis [49].
Diphtheria presents as an acute infectious disease af-
fecting the upper pulmonary tract caused by toxins pro-
duced by the bacterium. Characteristic features are
membranous pharyngitis with fever, enlarged anterior
cervical lymph nodes and edema of the soft tissues of
the neck [50]. This manifestation may lead to airway ob-
struction. The bacterium has a short incubation period
but untreated individuals may remain infectious for up
to 4 weeks. Both pertussis and diphtheria are potentially
fatal but easily preventable.
Leptospirosis
Leptospirosis is contracted either through direct contact
with infected animal urine, or urine-contaminated water
[10]. It can be found worldwide, but is predominantlyfound in tropical and subtropical countries (during rainy
season). Those taking part in water sports are most at
risk (an outbreak was reported among canyoning partici-
pants in Martinique, France) [51]. Increased cases are
also found in rural parts of a country where drinking
water can be easily contaminated with the bacteria; for
example, where wells have been poorly constructed [52].
Lately, there has been an increase in the number of
cases noted in Europe, with 97 cases identified in the
Netherlands in 2014 (4.6-fold increase in comparison to
previous years). Dutch tourists reported 33 cases of
leptospirosis, and most of these tourists acquired the
disease in Thailand [53].
The clinical course of leptospirosis is variable, with
symptoms from myalgia to fever with cough and shortness
of breath. Weil’s disease is its severest form and may
develop in 1–5% of cases. Patients progress from mild flu-
like symptoms to signs of organ failure (jaundice and
spontaneous bleeding) [54].
Where there is a high degree of clinical suspicion for
leptospirosis, treatment should be instigated. Diagnosis
is serological (via microscopic agglutination test [MAT]
for antibodies or PCR urine antigen test) but it may take
around 10 days after the onset of symptoms for these
tests to become positive [10]. In early mild disease,
penicillin and tetracycline antibiotics are effective [55].
Where the clinically more severe Weil’s disease is mani-
fest, patients may require organ support, and there is
little evidence that antibiotic use is of any benefit at this
stage [56]. In 2014, there were a total of 76 confirmed
cases of leptospirosis in England and Wales, of which 22
were acquired overseas; the majority of these were related
to recreational water exposure [57].
Tularemia
Recreational activities such as camping and visiting rural
and agricultural areas lead to increased risk to exposure to
the bacterium that causes tularemia [58]. Typically found
in the Northern Hemisphere, the number of infected cases
are underestimated and underreported [58]. Outbreaks
have been reported on Martha’s Vineyard (Massachusetts,
USA), Sweden and Finland in the last 15 years [58].
Francisella tularensis is the bacterium responsible for
what is a potentially fatal multi-systemic disease. Reser-
voirs of transmission are via ticks, biting flies, aerosol,
water exposure and food [58]. There are 4 identified
subtypes and clinical presentation depends on biotype,
method of transmission and port of entry. There are 6
major clinical presentations: ulceroglandular, glandular,
oculoglandular, oropharyngeal, pneumonic and typhoidal
[58]. Pulmonary features may consist of lobar pneumo-
nia, pulmonary effusions, infiltrates and hilar lymph-
adenopathy. Mortality in untreated pneumonic tularemia
can be up to 60% [59].
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isolation of the bacterium is hazardous and time con-
suming and most laboratories do not accept samples for
culture [60]. Agglutination and enzyme-linked immuno-
sorbent assay (ELISA) tests are the diagnostic tests of
choice [58]. Aminoglycosides are bactericidal against F.
tularensis and WHO recommend a 10-day course [61].
As an aside, F. tularensis subspecies tularensis (Type A)
is one of the most infectious pathogens known to man,
and these properties have led to tularemia being identified
as a potential weapon of bioterrorism [60].
Melioidosis
In South East Asia and northern Australia, a particular
Gram-negative organism called B. pseudomallei is re-
sponsible for an endemic of melioidosis disease [62].
Most commonly, the initial presentation is with low-
grade fever and atypical pneumonia, rapidly progressing
to multi-organ dysfunction. The mortality rate is very
high, ranging from 14 to 40% in general and up to 80%
with inappropriate antimicrobial therapy [9]. Difficulties
in culturing the bacterium responsible mean that under-
reporting is likely. The bacterium resides in soil and
water with transmission occurring mainly from percu-
taneous inoculation and inhalation. Exposure is most
likely to occur during the wet seasons in affected areas
or after natural catastrophes such as tsunamis.
Sporadic cases of the infection are now being reported
worldwide and manifestations of latent forms of the
disease are appearing some tens of years after initial ex-
posure [63]. As the number of international travellers
continues to rise, particularly to more rural parts of
South East Asia and northern Australia, this could lead
to an increase in the number of travel-related melioid-
osis cases in the future.
Early recognition of melioidosis is essential as the
bacterium is resistant to nearly all drugs given for
community-acquired pneumonia [63]. Current treatment
recommendations are ceftazidime or a carbapenem,
followed by eradication therapy with trimethoprim and
sulfamethoxazole for at least 3 months. There has been re-
cent interest in vaccine development due to both public
health and bioweapon concerns [64]. Mouse model vac-
cination has proved successful but to date there has been
no testing on humans [64].Tuberculosis (TB)
TB is a commonly found disease in certain parts of the
world. The risk of TB as a travel-related disease has not
been well established. A study from Italy in 2005 con-
cluded that over half of returned travellers with pneu-
monia or TB presented with a febrile illness but no
pulmonary symptoms [65]. TB can be transmitted onairplanes; a flight from Baltimore to Honolulu showed 4
of 15 passengers had a positive tuberculin skin test after
sitting in close proximity to a passenger with pulmon-
ary TB [6]. An overall probability of infection is 1 in
1,000 when a symptomatic source is present in close
proximity [6].
Risk is linked to longer-term travel to areas of higher
prevalence and proximity to affected individuals. Those
most at risk would be healthcare workers or individuals
visiting relatives [66]. TB risk in long-term travellers (of
greater than 3 months) is the same as the local popula-
tion in high endemic areas. A Dutch study showed there
was substantial risk to long-term travellers with an over-
all incidence rate of 3.5 per 1,000 person-months trav-
elled; however, no-one in this study had received a
Bacillus Calmette–Guérin (BCG) vaccine prior to travel-
ling, therefore incidence amongst those who have been
vaccinated is likely to be lower [66].
In recent years, multidrug-resistant TB (MDR-TB) and
extensively drug-resistant TB (XDR-TB) have become
increasingly important public health problems in many
countries (Eastern Europe, parts of Asia and Southern
Africa) [67]. The potential risk of transmission of par-
ticularly dangerous forms of TB requires renewed vigi-
lance. Since 2006, WHO have been informed of several
incidences of patients travelling (short-haul) by air with
MDR-TB and XDR-TB. In these cases, only close family
members have been later diagnosed with the disease, but
a potential risk to other travellers is possible given the
infectious nature of these strains of TB [67]. WHO have
since published guidelines for TB and air travel to pre-
vent the spread of the disease [67].
The main advice to clinicians is that the number of TB
infections is increasing, as are MDR-TB and XDR-TB
disease. The risks to most travellers in contracting TB
are small but increase depending on vaccination status,
length of travel, mode of travel and travel destination. If
pulmonary symptoms persist, despite negative standard
microscopy, culture and sensitivity testing, TB should be
added to the differential diagnosis list and should be
investigated appropriately.Pulmonary infections caused by fungi
Fungal infections in the absence of immunosuppression
generally occur in the Americas, where the exact destin-
ation of the traveller plays an important role in distinguish-
ing the fungus responsible.Histoplasmosis and coccidioidomycosis
Histoplasmosis should be considered in travellers return-
ing from the Midwest and central states of North
America, throughout Latin America and Central and
Trimble et al. Pneumonia  (2017) 9:1 Page 8 of 10Western Africa [68–70]. In 2013, approximately 300 cases
were reported in the South West region of China, the first
to be reported in Asia [68].
Coccidioidomycosis (Valley fever) has long been recog-
nized as a travel-related mycosis. Endemic areas are in
Southern California, Arizona and Central and South
America [69]. In returned travellers when common
causes for flu-like illness, non-productive cough and
pleuritic chest pain have been ruled out but symptoms
continue to persist, an underlying fungal infection
should be considered as a differential diagnosis.
Histoplasma capsulatum is endemic in North and
Latin America, while H. dubiosii is mainly found in
Central and Western Africa [70]. The organism grows
in soils enriched with bat and bird droppings, and hu-
man infection generally occurs after dust inhalation of
disturbed soil. The incubation period is relatively short,
and symptoms develop within 2 weeks of exposure
[69]. Reticulonodular shadowing on chest radiograph is
common, often with mediastinal lymphadenopathy.
Detection of the histoplasma antibody in urine or
serum is the most sensitive and widely used diagnostic
method [70]. Detection of coccidioidomycosis (Coccidioides
immitis) is similar but radiologically a cavitating pneumonia
may be seen [69].
In healthy individuals, fungal infections are generally
self-limiting. In those who are immunocompromised,
and/or go on to develop severe infection with systemic
complications, antifungals have been proven to be effect-
ive [70]. In contrast to histoplasmosis, coccidioidomycosis
infection generally leads to acquired immunity therefore
recurrence is unlikely [69].
Pulmonary infections caused by helminths
Pulmonary symptoms such as wheeze, breathlessness and
hemoptysis and an eosinophilia in a returned traveller
should prompt investigations for helminths. These infec-
tions may present as Loeffler’s syndrome (a result of larval
migration through the lungs) or tropical pulmonary eo-
sinophilia (hypersensitivity to lymphatic filarial worms).
Specific to schistosomiasis infections, Katayama syndrome
should be suspected in travellers returning from Africa or
South East Asia with fresh water exposure presenting with
fever, eosinophilia, dry cough and urticarial rash. Other
rare pulmonary presentation of helminths infections (such
as paragonimus, toxocariasis and dirofilariasis) should be
considered depending on travel destination and incuba-
tion period [71]. Treatment of these infections is generally
straightforward once the causative helminths have been
identified.
In 20% of hydatidosis (echinococcosis tapeworm) there
are pulmonary infiltrations. The majority of cases are
asymptomatic but following a leaking hydatid cyst in the
liver, patients may present with pleuritic chest pain,breathlessness and cough; a ‘water lily’ sign may be seen
on chest radiograph [72]. Surgery (aspiration) and anti-
parasitic drugs are required to fully treat the infection.Conclusion
The clinical spectrum of pulmonary infections in the
returned traveller is vast. History taking is paramount
(exact dates, contacts, length of stay, place of travel and
timings of onset of symptoms) and a high degree of
suspicion early on in the patient’s management is vital.
Most cases of pulmonary infections in travellers are
mild and self-limiting but travel-specific pulmonary
infections have high mortality rates if interventions are
not prompt.
The main modes of transmission for pulmonary in-
fections are by droplets or direct contact, hence the
importance of implementing protective barriers and
involving public health colleagues early to prevent fur-
ther transmission. Advice is always available from on-
line resources and specialist centers—as a clinician it is
important to familiarize yourself with guidelines and
protocols on travel-related infections. The WHO and
Centers for Disease Control and Prevention (CDC) are
continually updating guidelines on travel-related
infections.
Search strategy
We identified references for this review by searches in
different databases (PubMed, Ovid MEDLINE, Embase
and Cochrane) and references from relevant articles.
The following MeSH headings were used: “pulmonary”,
“respiratory”, “tropical disease” ‘travellers”, “travel”,
“returning traveller”.
The references were all further assessed by reading
the title and abstract. Only articles published in English
were included. We further assessed the references of all
selected publications. The final reference list was gener-
ated on the basis of relevance to the topics covered in
this review.
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